Using Cannabinoids & Fungus For The Development Of Medicine For Cancer

*** THIS IS A PRESS RELEASE ***
Cannabotech is advancing in the development of botanical medicine for cancer: It reports obtaining a worldwide exclusive license to use a unique fungus for the development and commercialization of products for the treatment of pancreatic and colon cancers

The studied fungus was found effective in killing pancreatic cancer cells and reducing the extent of cancerous tumors in animals; Cannabotech estimates it will present a prototype of the drug as early as the first half of 2023;

Using Cannabinoids & Fungus For The Development Of Medicine For Cancer - Credit PR
Using Cannabinoids & Fungus For The Development Of Medicine For Cancer – Credit PR

Herzliya, Israel – 2 January 2022 – Cannabotech, which develops, among other things, medical cannabis-based products and fungal extracts, reports it received exclusive use of a patent for the development of drugs based on the extract of Cyathus striatus fungus. The fungus is being researched in the laboratory of Professor Fouad Fares, an expert in molecular biology and cancer research at the Faculty of Natural Sciences at the University of Haifa.

According to the agreement signed between Cannabotech and Carmel, the economic company of the University of Haifa, Cannabotech will develop a botanical drug for pancreatic and colon cancers, based on a combination of cannabinoids from the cannabis plant with the fungus extract researched in Professor Fares’ laboratory, which has shown promising results and found to be effective in killing pancreatic and colon cancer cells, and reducing the extent of cancerous tumors in animals, without damaging healthy tissues. 

The THC WEEKLY newsletter, your best source for all things cannabis

Dr. Alex Weissman, an expert in organic chemistry and former director of R&D at the Chimagis Active Ingredients Factory (API), and Dr. Isaac Angel, an expert pharmacologist with more than 15 years of experience in leading drug development processes, will assist Cannabotech in the research process.

A few days ago, Cannabotech reported the results of a study according to which its CannaboBreast product for the treatment of breast cancer, based on a unique combination of cannabinoids and terpenes from the cannabis plant, combined with standard chemotherapy, resulted in an improvement of up to 6-fold in the killing of cancer cells compared to existing treatment (from 10% to 60% cancer cell mortality). 

Cannabotech CEO Elhanan Shaked said: “Cannabotech continues to advance according to its business plan. Along with our preventative medicine products that are already available today, we are operating in the medium-long term in a variety of clinical trials, the most significant of which is the development of a botanical drug for cancer-based on a unique combination of cannabinoids with the Cyathus striatus fungus.”

 Cannabotech CEO Elhanan Shaked - Credit: PR
Cannabotech CEO Elhanan Shaked Credit: PR

Professor Fouad Fares said: “We are pleased with the results achieved so far in animals and the critical reduction in the extent of cancerous tumors and with improved cancer cells’ mortality. The collaboration with Cannabotech enables us to accelerate the research and development process.”

 About Cannabotech:  

Cannabotech is an Israeli biomedical company that develops botanical solutions for preventive medicine and integrative medicine.  These solutions are based on combinations of active agents from the cannabis plant and fungi that work on two central systems in the human body: the endocannabinoid system and the immune system.

As part of the concept of integrative medicine, in the last two years, Cannabotech has been developing a series of 8 preparations based on unique combinations of botanicals from medical cannabis and fungus-based products, designed to help patients with cancer and chronic pain.  Upon completion of their development, the company’s goal is to designate the products to be integrated into oncology patients’ existing treatment protocol.   

At the same time, Cannabotech is working to develop a defined treatment protocol made available to physicians and technology for treatment customization. 

*** END OF PRESS RELEASE **

We would like to remind you that by subscribing to the THE WEEKLY newsletter you are the first to learn about new and exciting cannabinoid. Subscribe today and get our exclusive discounts on Delta 8, Delta 9, Delta 10 THC, THC-P, THC-O, HHC, THCV and other hemp-derived THC products.

Subscribe below to get your 25% discount code

The post Using Cannabinoids & Fungus For The Development Of Medicine For Cancer appeared first on CBD Testers.

Killing Cancer Cells: CannaboBreast Products Have Shown Promising Results

*** THIS IS A PRESS RELEASE ***
The cell model study examined the response of several types of cancer cells to CannaboBreast products developed by Cannabotech, with a product based on fungal extract and their activity in conjunction with standard chemotherapies;
The study was conducted under the guidance of Prof. Tami Peretz, Senior Oncologist at Hadassah Medical Center, former director of the Oncology Institute and former director of the Center for Malignant Breast Diseases at Hadassah Medical Center, and Dr. Isaac Angel, pharmacologist specializing in drug development;

Herzliya, Israel – December 20, 2021 – Cannabotech, which is engaged in, among other things, the development of medical products based on cannabis and fungal extracts, reports the results of a cell model study examining the efficacy of CannaboBreast products intended for integrative and/or concomitant oncology treatment with drug protocols (chemotherapy, biological and hormonal) for breast cancer. (Killing Cancer Cells)

Cannabotech - Showing An Improvement In Killing Cancer Cells (Credit: PR)
Cannabotech – Showing An Improvement In Killing Cancer Cells (Credit: PR)

The CannaboBreast product series is based on a unique combination of cannabinoids and terpenes from the cannabis plant. In parallel, Cannabotech intends to produce a treatment program that combines CannaboBreast products and nutritional supplements based on active ingredients extracted from several fungi. According to the study results, the composition of cannabinoids in combination with standard chemotherapy improved the effectiveness up to 6 times in killing cancer cells compared to existing treatment (from 10% mortality to 60% mortality of cancer cells).

The results showed that in addition to the effectiveness in killing cancer cells (as shown in the previous experiment in July), they have a synergistic effect in combination with oncological drug treatments that have been tested in known subtypes of breast cancer, while a specific treatment was adapted to each subtype. Along with the ability to increase existing treatments’ effectiveness, it may be possible to achieve increased efficacy of killing breast cancer cells while significantly reducing chemotherapy doses, which is also expected to dramatically reduce side effects and enable healing for more patients who currently cannot undergo conventional treatment due to the side effects.

The experiment also emphasized the importance of tailoring treatment, applying CannaboBreast products to different breast cancer subtypes, achieving other medical effects in combination with the appropriate drugs for each subtype. For example, while in some chemotherapy treatments a synergistic effect was achieved which enhanced the activity, in other cells representing different cancers, or in combination with other chemotherapies, no similar effect was seen, and even an opposite effect was achieved. In addition, Cannabotech is also developing a personalization system to provide physicians with the knowledge with which drug treatments and sub-cancer types should CannaboBreast products be combined.

The treatment is expected to be commercialized in the second half of 2022 and be integrated as part of Cannabotech’s integrative solutions concept, which are designed to incorporate existing treatment protocols in parallel with conventional drugs while providing supportive scientific information to the clinic physicians. About 50% of breast cancer patients receive additional integrative treatment in addition to conventional treatment (mainly herbal products, including cannabis), with one of the reasons for using the integrative product being to strengthen the immune system to improve the effectiveness of treatment and reduce side effects.,

Cannabotech CEO Elchanan Shaked said: “This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment in several cancers and are expected to be launched in Israel and the US in the second half of 2022, while the Company’s goal is to define a new standard for the medical cannabis industry. “

 Showing An Improvement In Killing Cancer Cells
Showing An Improvement In Killing Cancer Cells

Prof. Tami Peretz, Senior Oncologist: “A significant proportion of active cancer patients are currently treated with cannabis in parallel with conventional treatment. The integrative products developed by Cannabotech are unique in that they are developed to standards similar to those of the pharmaceutical industry and combine several active agents. The company’s products have demonstrated impressive and very promising activity in laboratory-tested cell cultures. Based on these experiments, there is room to start exploring the possibility of integrating the products in the treatment of breast cancer patients as well.”

Dr. Isaac Angel, Cannabotech’s pharmacological consultant, said: “The strong synergistic effect shown by the products in combination with the chemotherapies in different types of breast cancer cells has led to up to 6 times the effectiveness in cells killing. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products. We will continue to work to provide a cure for patients.”

About Cannabotech:

Cannabotech is an Israeli biomedical company that develops botanical solutions for preventive medicine and integrative medicine. These solutions are based on combinations of active agents from the cannabis plant and fungi that work on two central systems in the human body: the endocannabinoid system and the immune system.

As part of the concept of integrative medicine, in the last two years, Cannabotech has been developing a series of 8 preparations designed to help patients with cancer and chronic pain based on unique combinations of botanicals from medical cannabis and fungus-based products. Upon completion of their development, the company’s goal is to designate the products to be integrated into oncology patients’ existing treatment protocol.

At the same time, Cannabotech is working to develop a defined treatment protocol made available to physicians and technology for treatment customization.

*** END OF PRESS RELEASE **

We would like to remind you that by subscribing to the THC Weekly newsletter you are the first to learn about new and exciting cannabinoid. Subscribe today and get our exclusive discounts on Delta 8, Delta 9, Delta 10 THC, THC-P, THC-O, HHC, THCV and other hemp-derived THC products.

Subscribe below to get your 25% discount code

The post Killing Cancer Cells: CannaboBreast Products Have Shown Promising Results appeared first on CBD Testers.

Isreali Nextage Explores Effective Delivery of Psychedelic Compounds

Israel is one of the leading countries for medical cannabis research and has held this title for decades; since the 1960s to be exact. Now, they’re joining efforts to study the benefits of psychedelics in a clinical setting as well.

Of the main areas of focus is using psychoactive compounds to treat clinical depression and other psychiatric disorders. One Israeli company, Nextage Therapeutics, is looking specifically at utilizing ibogaine, along with their own patent delivery system, to better treat people with these conditions.

When it comes to treating psychological disorders and minimizing the risk of side effects, psychedelics are the way of the future. Check out our newsletter, The Delta 8 Weekly, to learn more about these incredible compounds as well as gain access to exclusive deals on flowers, vapes, edibles, and other products.


What are Psychedelics?

Psychedelic drugs are a subset of hallucinogens. They contain psychoactive compounds that are capable of altering a person’s mood, perception, and cognition; sometimes permanently. The active compounds are usually found in nature, like psilocybin or mescaline, but they can also be manmade, like LSD.

Psychedelics are known for causing ‘trips’, which is what the high is referred to. When a person is tripping, they may have altered perceptions of the world around them. Many people believe this is limited to visual and auditory hallucinations, but it can also include feeling, tasting, and smelling things that are not real, as well as a heightened sense of connection and understanding, and greater feelings of introspection.  

The trips that people most commonly associate with these types of the drugs are the ones in which a state of hallucinogenic delirium is reached, but that is not always the case. Many times, it is more of an experience than a trip, and something can be learned and achieved psychologically with every small dose.

The word itself, ‘psychedelics’, was first used in 1957 to recognize substances that were said to open the mind, however, the more accurate term for them is ‘entheogens’. This term was adopted, not necessarily for the sake of being scientific, but rather to allow the sector to operate without all the stigma attached to psychedelics from smear campaigns and restrictive policies throughout history. The term entheogen comes from Greek where it means ‘building the god within’.

Different psychedelics produce different trips. For example, with DMT you can expect a short high lasting less than 1 hour, whereas LSD, psilocybin, and mescaline trips can last up to ten hours. Some hallucinogens are more potent than others, like mushrooms vs acid. The active compounds are different in each drug so there is a lot of variation to the effects that can be felt.  

Some people experience bad trips in which negative, or even scary, hallucinations are experienced, and/or a rapid heartbeat, sweating, nausea, disorientation, and fatigue occur. There is indication that the majority of these symptoms can be controlled through proper dosing. This is why most modern-day, therapeutic users of psychedelics consume the drugs in micro-doses.

Nextage Pharmaceuticals and MindMend

According to Nextage Founder and CEO Abraham Dreazen, “there has been a shift in the last decade. The US Food and Drug Administration, for example, is starting to see quality of life as a factor in evaluating medicine, opening the door to these drugs.”

Earlier this year, Nextage signed a collaboration agreement with industry trailblazer Mindmend, to use their proprietary new technology known as Brain Targeting Liposome System (BTLS) – a delivery system Dreazen claims will “optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives.”

Ibogaine is a naturally occurring psychoactive substance found in Apocynaceae plant family in Gabon, a small coastal country in central Africa. Although minimal research exists, a handful of clinical studies found that Ibogaine and its derivatives can be used to combat addiction, and it was looked at particularly for the treatment of opioid addiction, for which the results were promising.

Unfortunately, when used at high doses over a longer period, there are potential side effects. In a recent press release, reps from MindMend explained that, “orally administered ibogaine and noribogaine present unacceptable safety risks due to their torsadogenic effects at high systemic concentrations.”

Simply put, there’s a moderate risk of heart attacks when using noribogaine. However, Dreazen believes that if the drug is administered using certain methods that better permeate the blood-brain barrier, so more of the drug actually reaches the brain rather than going to other parts of the body, including the heart. He described it as “the winning lottery ticket.”

Permeating the Blood-Brain Barrier

When it comes to treating psychological and neurological disorders, or really any other disease or condition affecting the brain, the main challenge is permeating the blood-brain barrier. The purpose of the blood-brain barrier is to protect the brain from foreign substances, and as such, can prevent up to 95% of molecules from reaching the brain.

So far, the most common way to work around that is by giving prescribing these drugs at extremely high doses, and that, needless to say, can have numerous unwanted and severe side effects. Using a more effective model, The BTLS platform, licensed from the Technion-Israel Institute of Technology, has been making use of a “liposomal vehicle with a unique targeting complex” that allows for blood-brain barrier permeation at much lower doses of various pharmaceutical agents.

This is a relatively well-known concept, but according to Dreazen, Nextage took it a step further and attached a “small arrow of seven amino acid peptides – essentially a very small protein – which is part of a much larger protein that is native to the brain and has a way of actively transporting the liposomal capsule through the blood-brain barrier. Once the capsule is drawn into the brain with the arrow, it gets lodged there and starts dissolving, facilitating release of the active material – the drug.”

What the Future Holds for Nextage

Nextage has been working in the drug delivery sector for 14 years and their daughter company, IMIO, is focused solely on psychedelics. The company completed most of required preclinical worked needed to determine the potential efficacy and generality of their new patent technology. They have already worked with CBD and THC-based medications and Nextage/IMIO plans to explore the potential of lysergic acid diethylamide (LSD).

Dreazen says LSD “is a really promising drug.” Its challenge is that when taken, people can “trip” for 15 to 17 hours, making it very unfeasible as a chronic treatment. But just like with ibogaine, he believes that if the dose can be reduced and the least amount possible gets into the body as opposed to the brain, “you could potentially get the same therapeutic effect without the longevity of the trip.”

“In the US, the psychedelic movement has exploded in the last 12 months,” Dreazen added. “I think psychedelics in Israel are just emerging, and we are the first public company to really put our teeth into it. Israel has always been in the forefront of research and development and we are committed to spearheading this industry.”

Final Thoughts

As you can see, conversations surrounding the use of psychedelics to treat mental health and neurological disorders is reaching nearly every corner of the globe, and the countries that have been more accepting of cannabis are also spearheading the medical psychedelic revelation. Psychedelics are here to stay, and in the very near future, we can expect to see a lot of these compounds being safely used in clinical and therapeutic settings.

Thank you for stopping by CBD TESTERS, your hub for all things cannabis and psychedelics-related. Make sure to Subscribe to The Delta 8 Weekly Newsletter to learn more and for exclusive deals on Delta 8Delta 10 THCTHCOTHCVTHCP & HHC.

The post Isreali Nextage Explores Effective Delivery of Psychedelic Compounds appeared first on CBD Testers.

A Win For Hemp, Agreement Is Reached in CA’s Assembly Bill 45

Assembly Bill 45 in California has long been a controversial piece of legislation, threatening to all but completely overturn the Golden State’s hemp market. However, according to the United States Hemp Roundtable, an agreement has finally been reached between hemp-industry advocates and Governor Gavin Newsom that would leave the state’s most lucrative hemp markets open and intact, should the bill pass as it’s currently written.

The cannabis industry can be complicated, and when it comes to confusing and senseless regulations, California usually takes the cake. Owning any business in California can be expensive and stressful, but if you’re working with cannabis, be prepared for some extra headaches. If you’d like to learn more about the industry, make sure to subscribe to The Medical Cannabis Weekly Newsletter. If you’re looking for exclusive deals on flowers and other products, check out our CBD Flowers Weekly NewsletterFor deals on the exotic cannabinoids, such as Delta 8Delta 10 THCTHCV, THCPTHC-O and even hemp-derived Delta-9 THC and HHC subscribe to the Delta 8 Weekly newsletter.


Is California Anti-Hemp? About Assembly Bill 45

California has always been a beacon of progressiveness; in pretty much all aspects but especially pertaining to the cannabis industry. As a matter of fact, California’s consumer marijuana market is the largest and among the least restrictive in the world. However, when it comes to hemp and CBD products, that’s a completely different ball game. California dispensaries need a special license to sell hemp flower and it’s illegal to infuse CBD in edibles, despite the fact that CBD is federally legal.

The old version of Assembly Bill 45 would have further regulated the production, distribution, and labeling of various hemp-infused products, ban hemp flowers and smokables. The California Department of Food & Agriculture would join with the state’s Bureau of Cannabis Control (BCC) to oversee the implementation of AB45, which would also outlaw CBD vapes and pens, hemp in beer, wine or spirits, and alcohol-based tinctures. In all, it would create a legislative, bureaucratic, and financial nightmare for hemp farmers, business owners, and other industry stakeholders.

“No state has sabotaged hemp as much as California,” said hemp veteran Richard Rose. “They aren’t content with killing the hemp food market for years through their legerdemain, and the birdseed market permanently,” said Rose. “They want to take CBD and smokable hemp down too.”

Furthermore, opponents of the bill claim that AB 45 is being championed almost entirely but lobbyists from competing industries who are looking to disadvantage the industrial hemp market in any way possible.

“The entire bill is crafted by outside lobbyists paid by big marijuana corporations working with HRT (the U.S. Hemp Roundtable) and the California Hemp Council, which have created a multi-million dollar bureaucracy,” said Chris Boucher, CEO at Farmtiva, a hemp ag services company and CBD consultant who also serves as a board member and treasurer at the Hemp Farmers Guild.

An Agreement Reached?

According to a written statement from the US Hemp Roundtable, the smokable hemp ban has been “replaced by a phase-in approach that will permit [its] sale to adults and the immediate manufacture of smokable products to be sold in other states.”

In this reworked bill, many of the negative facets of AB 45 would no longer apply. Various cannabinoids and hemp extracts would be permitted for use in food, beverages, dietary supplements, cosmetics, and pet food. Also, CBD flowers, vapes, and other smokeable items would not be regulated by the BCC.

It’s worth noting that Gavin Newsom is up for a recall in the state, with a vote set to take place on September 14th. That said, it makes sense that he’s backtracking various laws and bills he unsuccessfully supported and promoted in the past. The US Hemp Roundtable hopes to get a final vote on this upgraded version of AB 45 before the recall vote is underway.

Previously, the California Hemp Council had expressed its opposition to the bill, mainly because of its ban on smokable hemp/CBD flowers. The Hemp Roundtable says it coordinated with the CA Hemp Council to remove this oft-disputed provision.

Statement From The US Hemp Roundtable

“We’re excited to report that a final deal has been reached with Governor Gavin Newsom to move to final passage of AB 45, our long-term effort to explicitly permit the retail sale of hemp-derived extracts such as CBD in California. And a highlight of that compromise was the removal of language to ban hemp smokables in the state – replaced by a phase-in approach that will permit their sale to adults and the immediate manufacture of smokable products to be sold in other states.

We are deeply grateful for the leadership of Governor Gavin Newsom who met with Roundtable leadership and was deeply invested in securing passage of this bill. We are also appreciative for the leadership of the California Hemp Council, the voice of the state’s hemp industry, which partnered with the Roundtable, other California stakeholders, and, of course, our amazing bill sponsor, Rep. Cecilia Aguiar-Curry, to secure the final compromise. But mostly we are thankful to our grassroots California Hemp Supporters, who made sure that policymakers in Sacramento heard the concerns of hemp farmers, CBD businesses, and product consumers.

Of course, the battle is not yet over. While the bill has sailed through six legislative committees and the Assembly floor with only a handful of no votes, we still will have a final vote on the Senate floor next Wednesday, with one last vote on the Assembly floor next Thursday or Friday. We are asking Hemp Supporters ONE MORE TIME to head to our State Action Center to urge their state legislators to vote for this critical bill.”

The statement urges those from California to send a letter to state lawmakers supporting the reworked bill through USHR’s website.

Final Thoughts

 If everything goes according to plan, the vote on Assembly Bill 45 will take place sometime within the next week, then all it needs is a final signature from Gavin Newsom to go into effect. Check back with us for any important updates on this piece of legislation and other.

Thank you for stopping by CBD TESTERS, your hub for all things cannabis-related. And make sure to subscribe to The Medical Cannabis Weekly Newsletter for more articles like this one and exclusive deals on flowers, vape, edibles and other legal cannabis products.

The post A Win For Hemp, Agreement Is Reached in CA’s Assembly Bill 45 appeared first on CBD Testers.

A New Clinical Study To Evaluate The Effects of Cannabo-Nerve Combination On Chronic Neuropathic Pain

*** PRESS RELEASE *** San Francisco, CA – Herzliya, Israel, August 17, 2021 – Cannformatics, an early-stage biotechnology startup focused on the identification and application of saliva-based Cannabis-Responsive TM biomarkers and Cannabotech, a biomedical company developing medical solutions based on botanical combinations of cannabis extracts and functional mushrooms, today announced that Cannabotech has commissioned Cannformatics to conduct a study to evaluate the effects of Cannabotech’s Cannabo-Nerve combination on human patients suffering from chronic neuropathic pain. This study will also compare “MycoCann NeuroPain” to other leading off-the-shelf medical cannabis pain relievers that are currently being sold in the state of CA.

The CBD Testers Weekly Newsletters

“We are honored that Cannabotech chose Cannformatics to scientifically evaluate the impact of “MycoCann NeuroPain”. Pharmacometabolomic data in combination with study participant pain assessments are unique in their ability to provide insights into a product’s physiological mechanism of action and ability to manage chronic pain,” said Cannformatics CEO and Cofounder, Dr. Itzhak Kurek. “This is an exciting opportunity to support Cannabotech in bringing new hope to patients suffering with chronic neuropathic pain and deepen our understanding of pain related Cannabis-Responsive biomarkers.”

The study will be conducted under the supervision of an FDA regulated Institutional Review Board (IRB) in conjunction with Cannformatics’ Advisory Board members Dr. Donald Abrams and Dr. Bonni Goldstein. Subject to receiving IRB approval, Cannformatics will begin recruiting participants for the study. People interested in participating the study may sign up for study updates HERE.

CBD / Delta 8 / Delta 10 / THCV / THC-O Wholesale Opportunities

Elchanan Shaked, CEO and Chairman of Cannabotech, said: “For the past two-years Cannabotech has built a rigorous scientific pipeline for the development of cannabis- and mushroom-based products. The unique formulation that will be tested combines an exact composition of 13 cannabinoids and terpenes with mushroom extracts for the purpose of reducing chronic neuropathic pain without THC-related psychoactive effects. Cannformatics’ technology will provide novel insights obtained in a real-world setting, adding an important layer to the high- quality scientific evidence necessary to gain the support of the medical community ahead of a planned launching of “MycoCann NeuroPain” in the second half of 2022.”

About Cannformatics, Inc:
Cannformatics is an early-stage biotechnology startup focused on the personalization of medical cannabis treatment through the identification and application of Cannabis- Responsive biomarkers found in saliva. The company’s mission is to deliver recommendations for predictable and repeatable science-based medical cannabis treatment to improve health and quality of life. The company is now pursuing identifying Cannabis-ResponsiveTM biomarkers related to autism spectrum disorder in children.
Cannformatics is headquartered in San Francisco, CA.

About Cannabotech, Inc:
Cannabotech is an Israeli biomedical company developing botanical solutions for preventive & integrative medicine. These solutions are based on combinations of active ingredients from the cannabis plant and medicinal mushrooms focusing on two main systems in the human body: the endocannabinoid (ECS) system and the immune system. The Company’s goal is to develop products that can be integrated into existing oncology treatment protocols. Cannabotech is developing a series of eight formulas designed to help patients suffering from five cancer types (Pancreatic, Colorectal, Breast, Lung & Prostate), and minimize chemotherapy-induced chemotherapy-induced neuropathic pain (CINP) and chemotherapy-induced nausea and vomiting (CINV).
Cannabotech is headquartered in Herzliya, Israel.

*** END OF PRESS RELEASE ***

The post A New Clinical Study To Evaluate The Effects of Cannabo-Nerve Combination On Chronic Neuropathic Pain appeared first on CBD Testers.

CanBreed Introduced The World’s First Fully Stable and Genetically Uniform Cannabis Hybrid Seeds

(PRESS RELEASE): Marketing of CanBreed stable Cannabis seeds, which will enable standardization in the Cannabis industry, is expected during 2021

CanBreed, a leading Israeli Cannabis genetics and seeds company engaged in the development and enhancement of Cannabis seeds, is proud to announce that it has completed the development of the first known stable and uniform Cannabis hybrid seeds in the world. In doing so, the company brings a solution to the main problem of the Cannabis industry that suffers from lack of uniformity and standardization due to the absence of genetic stability in Cannabis plants resulting also in high production costs that hamper growers’ profits. Stable and uniform hybrid seeds, with improved genetics, are the solution to both these problems.

In June 2020, after more than three years of strenuous research and development, CanBreed completed the development of the first uniform homozygous (100% stable) Cannabis parental lines. Crosses between these parental lines creates the world’s first true F1 hybrids Cannabis seeds. The company has completed the first F1 hybrid seed production cycle in the world. These stable hybrids will ensure the reproducibility, standardization and high quality of raw material for the entire Cannabis industry.

In the present cycle, CanBreed produced dozens of stable new varieties from diverse genetic backgrounds, which will be planted for testing in CanBreed’s breeding and seeds production farm that is at its final stages of construction. At the end of the selection phase, which is expected to be completed during the first half of 2021, the seeds of the varieties that fit industry demands will be marketed.

Unlike most agricultural crops that are grown from stable seeds, Cannabis plants are presently propagated vegetatively through cloning by using cuttings from mother plants. Cloning is done in order to ensure genetic identity between the offspring and the mother plants, which until now could not be achieved by growing Cannabis from seeds because there were no stable Cannabis seeds.

The main cause of the lack of standardization that exists in the industry is that the raw material extracted from Cannabis plants grown from cuttings is not reproducible. On one hand, cloning ensures a genetic identity between the offspring and the mother plant, but on the other hand, the cloning methods that exist today (such as tissue cultures) do not prevent the aging of the mother plants. Thus, similar to the natural aging processes that take place in any living organism (including humans) mother plants accumulate aging related mutations and changes in the

genome that cause differences in the chemical profile of the plant. This leads to the fact that despite being genetically identical, the chemical profile of offspring differs from those of the young mother plants.

The reason that until now it was not possible to get reproducible and uniform Cannabis products by growing Cannabis from seeds is that all Cannabis strains in the market today are heterozygous (genetically unstable) and crossing between two unstable Cannabis strains will produce seeds with high genetic variation. Thus, today every seed grown on a plant produced from the crossing of two unstable plants is genetically different from all the other seeds on the same plant. The fact that all the seeds are different from each other in a particular Cannabis plant means that plants grown from these seeds, even though they originated from the same plant, will have a different genetic profile. Therefore, to this day, the only method available for Cannabis growers to preserve the genetic identity of the offsprings has been through cloning of mother plants.

CanBreed's genetically uniform Cannabis hybrid seeds
CanBreed’s genetically uniform Cannabis hybrid seeds

The solution to the problem comes from the seeds industry.

In the agricultural industry, plants, such as tomatoes, corn, watermelon, etc, are grown exclusively from stable seeds thus ensuring genetic uniformity that enables high quality growing and reproducibility of the products.

Stable seeds, such as tomato seeds, corn, etc. used in the agricultural industry, are produced from homozygous parental lines (plants that are 100% genetically stable). The procedure of creating homozygous plants requires dedicated resources, unique agronomic and scientific knowledge and consumes considerable time. Crossing of two different homozygous plants will produce seeds that are genetically identical, meaning that all the resultant seeds of the crossing will have the same DNA (identical twins). These seeds are known in the seed industry as F1 Hybrid seeds. Using F1 Hybrid seeds will always result in plants identical to each other, thus eliminating the need for cloning of Cannabis and Hemp and ensuring the reproducibility and uniformity of the raw material extracted from the plant.

In parallel to the development of stable seeds, CanBreed is developing YieldMaxTM, an enhanced genetic trait platform, which contains all the agronomic traits that Cannabis and Hemp growers need for consistent, high-quality, cost efficient mass-scale cultivation. The breeding of the YieldMaxTM traits is achieved by using CRISPR-Cas9, an innovative gene editing technology. Upon completion of the YieldMaxTM development, the stable seeds of CanBreed will contain also these traits.

At November, CanBreed announced that as part of its project to develop a Powdery Mildew resistance trait, which is one of the traits in the YieldMaxTM platform, the company performed and identified an editing event in the Cannabis plant genome using CRISPR-Cas9. This report follows the company’s announcement on signing a commercial license agreement for CRISPR-Cas9 foundational patents with the CRISPR patent owners – Corteva Biosciences and Broad Institute

(of MIT and Harvard). The CRISPR developers were recently awarded with the Nobel Prize in Chemistry for 2020.

The company further announced recently that it had purchased a 3.5-acre farm in San Diego county in California. A production facility of stable hemp seeds intended for the US market is planned to be set-up at the farm. The farm’s initial output is expected to be about 12.5 million seeds annually, which will subsequently increase to about 50 million seeds annually.

Ido Margalit, CanBreed CEO: “The company’s achievement comes after nearly four challenging years of development as the company faces extensive knowledge and infrastructure gaps in the field of Cannabis seeds, and in parallel invests in market education regarding the feasibility of developing stable Cannabis and Hemp seeds. CanBreed’s achievement, first of its kind in the world, positions the company at the forefront of this emerging industry that will provide a solution to a huge global potential market of Cannabis and Hemp seeds, estimated at hundreds of millions of dollars a year”.

About CanBreed

Founded in 2017, CanBreed’s goal is to increase the profitability of Cannabis farming, while enabling growers to supply uniform and high-quality raw material to Cannabis-based industries. The company is based in Israel, where the use of Medical Cannabis is legally permissible, operating one of the largest R&D Center and a seed trialing and production facility in the country. CanBreed is managed and staffed by a multidisciplinary team of dedicated seed and genetics professionals.

The post CanBreed Introduced The World’s First Fully Stable and Genetically Uniform Cannabis Hybrid Seeds appeared first on CBD Testers.

First Ever Marketplace Exclusively For Delta 8 THC Products

Introducing a first-of-its-kind marketplace for all things delta 8 THC, Direct Delta 8. Direct Delta 8 will serve as the premier online retailer for a growing array of high-quality brands and products.

Why now, why delta 8? The founders of Direct Delta 8 saw a need for a safe, reliable, and enjoyable shopping experience for consumers looking for products. Delta 8 is federally legal thanks to the 2018 Farm Bill.Advertisement

According to the bill, also known as the Agricultural Improvement Act of 2018, “All derivatives, isomers, and cannabinoids in hemp are legal provided that the final products contain less than 0.3% delta 9 THC.”

To learn more about Delta 8 and get deals on flower and other products, subscribe to the Delta 8 Weekly Newsletter


So, not only can consumers legally reap the benefits of delta 8, but they can also rest assured that they’re only getting the highest quality products. Direct Delta 8 is beginning its venture with industry leading brands such as 3Chi, Delta Effex, Skyhio, Urb Finest Flowers, and CannaAid. Users can enjoy vape cartridges that conveniently fit onto a variety of devices, or, they can choose from delta 8 edibles or tinctures.

Like CBD and cannabis itself, delta 8 as a natural therapeutic is not a new concept. Research from various sources, including the National Cancer Institute, has shown delta 8 to have positive effects. If you’re wondering how delta 8 compares to CBD and THC, it can be described as offering a calming body feeling.

While CBD offers no psychoactive effects at all, delta 8’s effects are milder than THC. Therefore, delta 8 may offer promising benefits for individuals who haven’t found relief with CBD but aren’t able to safely or legally access THC. Of course, it’s important for anyone interested in a new remedy to first consult their healthcare provider.


About Direct Delta 8:
Direct Delta 8 was founded in 2020 by a team of individuals passionate about cannabis and its derivatives. Not only does Direct Delta 8 strive to provide the highest quality products and the best customer experience, but it also wants to help people learn more about delta 8 and it’s exciting potential.

SOURCE: PR NEWSWIRE

The post First Ever Marketplace Exclusively For Delta 8 THC Products appeared first on CBD Testers.

Succesful feasibility study for the development of topical medical cannabis products

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a feasibility study for the development of IP protected, homogeneous, topical medical Cannabis products for the treatment of skin inflammation, including psoriatic lesions. (PRESS RELEASE)

To learn more about medical cannabis, subscribe to the Medical Cannabis Weekly Newsletter


Product development of such topical medical Cannabis products based on AKVANO® is being conducted under a collaboration between Cannassure and Lipidor AB (“Lipidor”), a Swedish topical drug development company, owner of the proprietary drug delivery platform technology AKVANO, which was signed in December 2019. The development project budget is partially funded by the Israeli Innovation Authority, by a non-dilutive grant.

The product under development is an incorporation of cannabinoids with AKVANO®, a topical drug delivery platform. Successful development of the product will allow localized administration of a precise dosage of cannabinoids using a spray, in a technology that allows for prolonged contact and optimal penetration of the active ingredient into the skin.

As part of the feasibility study, AKVANO® technology and cannabinoids were tested for compatibility, and it was found that the cannabinoids can be successfully combined in the AKVANO® system for a homogeneous, uniform and stable formulation. Cannassure tested the degree of product penetration into the skin by using known and acceptable models and found significant penetration of active ingredients into the skin tissue. This enhanced penetration may increase the therapeutic potential of the product. Based on these results, Cannassure will proceed to accelerated development stages and more advanced testings.

According to the agreement, Cannassure has informed Lipidor on its intention to start negotiating an exclusive global license for the use of Lipidor’s technology for the development of cannabinoids based topical therapeutics products for the treatment of indications to be chosen by Cannassure.  

The main guidelines for the licencing agreement, including royalties to be paid to Lipidor on product sales, were defined in the collaboration agreement.

According to estimates, the global market for products for the treatment of psoriasis is expected to reach 21.1 billion dollars by 2022. The current global market for topical products for the treatment of psoriasis is valued at 7 billion dollars, and the global market for topical pain treatment products is projected to reach 13 billion dollars.

The product development of topical treatments based on cannabinoids is in line with Cannassure’s strategy focused on the development and commercialisation of innovative medical cannabis products based on established drug delivery systems and formulations for enhanced therapeutic value. The product development is performed under the Israeli Medical Cannabis regulation, which allows a short development process.

About Cannassure Therapeutics Ltd.

Cannassure Therapeutics Ltd. (TASE:CSURE) is a leading, world class, trusted developer and provider of top-quality-grade medical cannabis products and pharmaceutical cannabinoid medicines, addressing a broad range of unmet medical needs.

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

Looking to learn more about Medical Cannabis Research? Subscribe to the Medical Cannabis Weekly newsletter.

The post Succesful feasibility study for the development of topical medical cannabis products appeared first on CBD Testers.

U.K. Regulators Launch Crackdown On CBD And Issue Health Warning

U.K. Regulators have warned the country’s CBD industry to comply with Novel Food rules or face having their products taken off their shelves.

The Food Standards Agency has also issued a health warning to mums-to- be and those taking medication not to use CBD. In a press release today the FSA has given the industry a little over a year to comply with its new novel food guidelines. 

The press release reads as follows: “The FSA has set a deadline for CBD businesses to provide more information about CBD products and their contents. It also advises vulnerable groups not to take CBD, and healthy adults to take no more than 70mg a day.

The Food Standards Agency (FSA) is giving the CBD industry a deadline of 31 March 2021 to submit valid novel food authorisation applications. After 31 March next year, only products which have submitted a valid application will be allowed to remain on the market. The authorisation process ensures novel foods meet legal standards, including on safety and content.

Keep yourself updated with the latest regulatory changes! Subscribe to the CBD Business Weekly Newsletter.

Local authorities enforce the novel food legislation. They have been advised that businesses should be able to sell their existing CBD products during this time provided they are not incorrectly labelled, are not unsafe to eat and do not contain substances that fall under drugs legislation.

In addition, the FSA is today advising those who are pregnant, breastfeeding or taking any medication not to consume CBD products. Healthy adults are also advised to think carefully before taking CBD, and the FSA recommends no more than 70mg a day (about 28 drops of 5% CBD) unless under medical direction. This new precautionary advice is based on recent findings by the government’s Committee on Toxicity (COT).

Emily Miles, Chief Executive of the Food Standards Agency, said:

“CBD products are widely available on the high street but are not properly authorised. The CBD industry must provide more information about the safety and contents of these products to the regulator before 31 March 2021, or the products will be taken off the shelves. 

The Thorny Issue Of U.K. CBD Regulation In A Post-Brexit World

Also today, we are advising that CBD could be risky for vulnerable groups, and suggesting an upper limit of 70mg a day for everyone else taking the product.

The actions that we’re taking today are a pragmatic and proportionate step in balancing the protection of public health with consumer choice. It’s now up to industry to supply this information so that the public can be reassured that CBD is safe and what it says it is.”

Professor Alan Boobis, Chair of the Committee on Toxicity, said: 

“My committee has reviewed the evidence on CBD food products and found evidence there are potential adverse health effects from the consumption of these products. We are particularly concerned about pregnant or breast-feeding women and people on medication.

“We don’t know enough to be sure about such a risk but I am pleased with the sensible and pragmatic approach the FSA is taking. The committee will continue to keep these products under review in the months ahead.”

CBD Testers will be proving reaction from the industry as we receive it. For more updates and articles like this one, subscribe to the CBD Business Weekly Newsletter.  

The post U.K. Regulators Launch Crackdown On CBD And Issue Health Warning appeared first on CBD Testers.

MJardin Group Inc. Announces Partnership with Robes Inc.

TORONTO and DENVER, Nov. 12, 2019 (GLOBE NEWSWIRE) — MJardin Group, Inc. (“MJardin” or “the Company”) (CSE: MJAR) (OTCQX: MJARF), a leader in premium cannabis production, is pleased to announce that it has entered into a partnership with Robes Inc. (“Robes”), a luxury cannabis brand house focused on bringing exotic and rare strains to Canadian consumers. Under the […]

The post MJardin Group Inc. Announces Partnership with Robes Inc. appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.